Colon cleansing system maker Motus files for IPO to raise $29M

Motus GI, maker of the Pure-Vu system to clean colons during colonoscopy procedures, filed for an IPO to raise $29 million.

Israel-based Motus GI announced its intention to hold an initial public offering to raise as much as $28.8 million, according to an SEC filing on Friday.

The company developed the Pure-Vu system that is FDA-approved and connects to standard colonoscopy devices, allowing physicians to clean poorly prepped colons for the procedure so they can get a clearer image of the colon mucosa.

Motus, which is based in Tirat Carmel, Israel, said in the filing it plans to list on the Nasdaq under the symbol MOTS. Named as joint bookrunners for the deal are Piper Jaffray and Oppenheimer & Co. Pricing terms weren’t disclosed.

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

The Pure-Vu system allows for decreased dependence on precolonoscopy preparation by the patient, who typically must be on a liquid diet for at least 24 hours ahead of the procedure and generally must drink as much as four liters of a purgative and spend up to 12 hours before the exam emptying their bowels. About 15 million colonoscopies are performed in the U.S. every year, the company said.

Motus was founded in 2008 as part of the NGT incubator before it was spun out into a new company in 2011 to focus on the Pure-Vu system.

Read more on

Suggested Articles

Boston Scientific’s deep brain stimulation implant for treating Parkinson’s disease has been approved by the FDA as safe to use within an MRI.

The FDA approved a new device for people suffering from advanced heart failure who are not able to receive treatment from other devices.

Alcon has announced plans to launch its daily disposable contact lens in the U.S. made from a new material.